Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden - HPV Elimination

Region Stockholm0 个研究点目标入组 150,000 人开始时间: 2021年2月1日最近更新: 2021年4月26日

适应症

试验速览

暂无简介。

•Eligible women will include resident women within the age range of 23-25 due for invitation to organised cervical cancer screening who consent to participate in the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 150000
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Known history of severe allergic reaction or hypersensitivty to any of the components of the HPV vaccine.
•oFor GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate
•2.Known history of immune-related disorders
•3.Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.
•4.Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose
•5.Current pregnancy (reported)
•6.Hysterectomized women

发起方